疏血通注射液联合前列地尔对行经皮冠状动脉介入术的急性心肌梗死患者的影响

摘要

Objective To investigate the impact of shuxuetong injection combined with alprostadil on acute myocardial infarction patients undergoing PCI.Methods A total of 90 patients with acute myocardial infarction were selected in the Fourth People's Hospital of Liaocheng from March 2015 to March 2016,and they were divided into control group and test group according to random number table,each of 45 cases. Patients in the two groups received conventional treatment and PCI after admission,thereinto patients in control group received alprostadil before PCI,patients in test group received shuxuetong injection combined with alprostadil before PCI;both groups continuously treated for 10 days.Clinical effect, time to recanalization,LVMI,LVPWT,LVEDD,LVEF,CK-MB and cTnT before and after treatment,and incidence of MACE during hospitalization were compared between the two groups.Results Clinical effect in test group was statistically significantly better than that in control group,meanwhile time to recanalization in test group was statistically significantly shorter than that in control group(P<0.05). No statistically significant differences of LVMI,LVPWT,LVEDD or LVEF was found between the two groups before treatment(P>0.05);compared with control group,LVMI in test group was statistically lower after treatment,LVPWT was thinner,LVEDD was shorter,while LVEF was higher(P<0.05). No statistically significant differences of CK-MB or cTnT was found between the two groups before treatment(P>0.05),while CK-MB and cTnT in test group were statistically significantly lower than those in control group after treatment(P<0.05). Incidence of MACE in test group was statistically significantly lower than that in control group during hospitalization(P<0.05).Conclusion  Shuxuetong injection combined with alprostadil can effectively improve the clinical effect in acute myocardial infarction patients undergoing PCI,shorten the time to recanalization,inhibit the ventricular remodeling,improve the cardiac function,relieve the myocardial injury and reduce the risk of MACE.%目的 探讨疏血通注射液联合前列地尔对行经皮冠状动脉介入术(PCI)的急性心肌梗死患者的影响.方法 选取2015年3月—2016年3月聊城市第四人民医院收治的急性心肌梗死患者90例,采用随机数字表法分为对照组和试验组,每组45例.两组患者入院后均接受常规治疗并行PCI,对照组患者于PCI前给予前列地尔治疗,试验组患者于PCI前给予疏血通注射液联合前列地尔治疗;两组患者均连续治疗10 d.比较两组患者临床疗效,血运再通时间,治疗前后左心室质量指数(LVMI)、左心室后壁厚度(LVPWT)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白T(cTnT),并观察两组患者住院期间主要不良心血管事件(MACE)发生情况.结果 试验组患者临床疗效优于对照组,血运再通时间短于对照组(P<0.05).治疗前两组患者LVMI、LVPWT、LVEDD、LVEF比较,差异无统计学意义(P>0.05);治疗后试验组患者LVMI低于对照组,LVPWT小于对照组,LVEDD短于对照组,LVEF高于对照组(P<0.05).治疗前两组患者CK-MB、cTnT水平比较,差异无统计学意义(P>0.05);治疗后试验组患者CK-MB、cTnT水平低于对照组(P<0.05).试验组患者住院期间MACE发生率低于对照组(P<0.05).结论 疏血通注射液联合前列地尔可有效提高行PCI的急性心肌梗死患者的临床疗效,缩短血运再通时间,抑制心室重构,改善心功能,减轻心肌损伤,减少MACE的发生.